Handelsbanken Fonder’s Pacira BioSciences PCRX Stock Holding History

Handelsbanken Fonder’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17,923	Closed	-$270K	–	1567
2024 Q3	$270K	Buy	17,923 +6,000	+50%	+$103K	﹤0.01%	1437
2024 Q2	$341K	Buy	11,923 +2,300	+24%	+$65.5K	﹤0.01%	1332
2024 Q1	$281K	Hold	9,623	–	–	﹤0.01%	1408
2023 Q4	$325K	Hold	9,623	–	–	﹤0.01%	1358
2023 Q3	$295K	Hold	9,623	–	–	﹤0.01%	1316
2023 Q2	$386K	Hold	9,623	–	–	﹤0.01%	1208
2023 Q1	$393K	Hold	9,623	–	–	﹤0.01%	1130
2022 Q4	$372K	Hold	9,623	–	–	﹤0.01%	1126
2022 Q3	$512K	Hold	9,623	–	–	﹤0.01%	952
2022 Q2	$561K	Hold	9,623	–	–	﹤0.01%	955
2022 Q1	$734K	Hold	9,623	–	–	﹤0.01%	946
2021 Q4	$579K	Hold	9,623	–	–	﹤0.01%	1249
2021 Q3	$539K	Hold	9,623	–	–	﹤0.01%	1313
2021 Q2	$584K	Buy	9,623 +2,800	+41%	+$177K	﹤0.01%	1264
2021 Q1	$478K	Hold	6,823	–	–	﹤0.01%	1227
2020 Q4	$408K	Hold	6,823	–	–	﹤0.01%	1264
2020 Q3	$410K	Hold	6,823	–	–	﹤0.01%	1091
2020 Q2	$358K	Buy	+6,823	New	+$285K	﹤0.01%	1123

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Handelsbanken Fonder's PCRX Position: Q4 2024 in Review

Handelsbanken Fonder sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 17,923 shares — an estimated $270K sold.

Handelsbanken Fonder first reported a position in PCRX in Q2 2020 and held it in 18 quarters. The position peaked at $734K in Q1 2022. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

Handelsbanken Fonder reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
Handelsbanken Fonder sold 17,923 Pacira BioSciences shares in Q4 2024, an estimated $270K.
Handelsbanken Fonder first reported a position in Pacira BioSciences in Q2 2020 and held it in 18 quarters.
Handelsbanken Fonder's Pacira BioSciences position peaked at $734K in Q1 2022.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.